Wei Deng

Liquiritigenin suppresses osteoclastogenesis via multi-target mechanisms involving NF-κB/PI3K-AKT signaling pathways and metabolic reprogramming

Network pharmacology and in-depth blood proteomics reveal the mechanism of Buqi Tongluo capsules in treating bone destruction in osteoarthritis

Neoandrographolide inhibits mature osteoclast differentiation to alleviate bone loss and treat osteoporosis

Buqi-Tongluo Decoction inhibits osteoclastogenesis and alleviates bone loss in ovariectomized rats by attenuating NFATc1, MAPK, NF-κB signaling

Isonardosinone suppresses osteoclastogenesis through TRAF2/TRAF6-mediated disruption of calcium signaling and coordinate inhibition of MAPK/NF-κB pathways

Corylifol A suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss via attenuating ROS production and impairing mitochondrial function

Sophoraflavanone G Inhibits RANKL-Induced Osteoclastogenesis via MAPK/NF-κB Signaling Pathway

Isoginkgetin Inhibits RANKL-induced Osteoclastogenesis and Alleviates Bone Loss

CCL5: a novel biomarker in a diagnostic model for bone metastasis in prostate cancer

Identification of Risk Factors for Primary Osteoporosis: The Role of Cervical Ligament Ossification

Isoimperatorin attenuates bone loss by inhibiting the binding of RANKL to RANK

Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding

Panax notoginseng saponins inhibits oxidative stress- induced human nucleus pulposus cell apoptosis and delays disc degeneration in vivo and in vitro

Dehydromiltirone inhibits osteoclast differentiation in RAW264.7 and bone marrow macrophages by modulating MAPK and NF-κB activity